FDA to consider RSV vaccine for adults in their 50s

Respiratory syncytial virus vaccinations could soon extend to adults aged 50-59. 

Arexvy, which was initially approved by the FDA in May 2023 for administration in adults over 60, has been granted priority review in the U.S. for use in adults ages 50-59.

If approved, it will become the first RSV vaccine available for the age group, according to a Feb. 6 news release. 

The FDA is slated to make a decision on the drug's approval for the new age group by June 7.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy
.
 

Articles We Think You'll Like